Maryland Attempting to Pass Bill That Would Benefit Military Veterans By Providing Them ‘Cost-Free Access’ to Psychedelics

Maryland Senate recently filed a bill that, if passed, would create state funding for free access to psychedelics (psilocybin, MDMA, ketamine, etc) for military veterans who suffer from post-traumatic stress disorder (PTSD). The bill would also support the research of the therapeutic potential of psychedelics.

The purpose of the bill is to establish what’s known as the Post-Traumatic Stress Disorder Alternative Therapies Fund[1]. The money would fund research in psychedelics as well as provide “cost-free access to alternative therapies” for military veterans.

Additionally, the bill, sponsored by Sen. Sarah Elfreth (D), would require regulators to periodically “consult with the Department of Veterans Affairs, the John Hopkins University, the University of Maryland, Sheppard Pratt, and Walter Reed National Military Medical Center” on the use of psychedelics for PTSD treatment.

If the bill goes through and is received positively, then it could set the groundwork for future legislation on providing residents with regulated access to psychedelics for therapeutic use.

The bill currently has nine senators as cosponsors and is scheduled to receive a hearing during the state’s Budget and Taxation Committee on March 2 of this year.

In order for the bill to pass, the Maryland Department of Health would need to submit a report of “initial findings and recommendations” to the governor and legislation by December 1, 2022[2]. In two years’ time would come another deadline for findings and recommendations based on the studies that were conducted specifically through the PTSD fund.

Maryland’s proposal is just one of many as states move towards the decriminalization of psychedelics.

In a recent Ketamine News article, we covered how Washington State Sens. Jesse Salomon (D) and Liz Lovelette (D) are pushing to legalize psilocybin.

The movement to decriminalize psilocybin in the US originated in the late 2010s, with Denver, Colorado becoming the first city to accomplish its goal in May 2019. Oakland and Santa Cruz, California followed closely behind, both successfully decriminalizing psilocybin by January 2020.

In November of the same year, voters passed the Oregon Ballot Measure 109, effectively making Oregon the first state to decriminalize psilocybin while legalizing it for therapeutic use.

These efforts come in the aftermath of the rapid onset of cannabis legalization in the United States, occasionally referred to as the Green Rush[3].

According to an article written by Dustin Marlan for The Appeal, titled, “The Movement to Decriminalize Psilocybin, Explained,” he writes, “Psilocybin reform is an important development for at least two reasons. First, psilocybin is a promising compound that, if studied and used appropriately, can provide benefits to many. Second, psilocybin reform may spur a radical rethinking of the prohibition on other Schedule I substances, and can thus be a catalyst toward ending the racist and draconian War on Drugs.”[4]

More and more states are pushing for the decriminalization of psilocybin as studies have shown that it is an effective treatment option for depression, anxiety, and substance abuse.

Kaeli Swaggerty holds a B.A. in English from the University of Tennessee, Knoxville. Connect with her about bringing awareness to mental health issues on LinkedIn.

Sources:

“Maryland SB709.” TrackBill, https://trackbill.com/bill/maryland-senate-bill-709-post-traumatic-stress-disorder-alternative-therapies-fund-establishment-david-perez-military-heroes-act-end-22-a-day/2218272/#:~:text=Establishing%20the%20Post%2DTraumatic%20Stress,any%20other%20money%20from%20any.

Jaeger, Kyle. “Maryland Senate Bill Would Provide ‘Cost-Free Access’ to Psychedelics for Military Veterans.” Marijuana Moment, 9 Feb. 2022, https://www.marijuanamoment.net/maryland-senate-bill-would-provide-cost-free-access-to-psychedelics-for-military-veterans/.

Overland, Martha Ann. “The Green Rush Begins: Investors Get in on Pot’s Ground Floor.” NPR, NPR, 16 Feb. 2014, https://www.npr.org/2014/02/16/277691480/the-green-rush-begins-investors-get-in-on-pots-ground-floor.

“The Movement to Decriminalize Psilocybin, Explained.” The Lab by the Appeal, https://theappeal.org/the-lab/explainers/the-movement-to-decriminalize-psilocybin-explained/.

Ketamine Media Launches Industry Leading Psychedelic Therapy Network

KETAMINE MEDIA (LLC). is proud to announce the launch of their Psychedelic Therapy Network (PTN), a digital ecosystem linking psychedelic medicine providers to individuals seeking innovative new treatment options in the world of mental healthcare.

Psychedelic Therapy Network (PTN) is the culmination of a long endeavor to provide patients looking for alternative care with a single point of reference and comprehensive resource for finding psychedelic medicine providers in their regions. The collection of digital assets will effectively reach potential candidates in virtually every zip code across North America.

Ketamine Media felt that creating the network was not just something that would make patient lives easier but also a critical tool for spreading awareness and education about psychedelic medicine. With the nation facing the worst mental health crisis in its history, new methods and modalities of treating mental health conditions are needed.

“The Psychedelic Therapy Network was designed to assist our partners in effectively raising awareness at scale. But it’s really designed with patients in mind. When we created it [the Psychedelic Therapy Network], we wanted to take a patient-first approach. The psychedelic medicine space can be confusing, and our team wanted to build something that helps people learn more about psychedelic medicine and unites them with qualified, passionate providers once they decide that this approach is right for them.”
Chris Walden, CEO and Co-founder, Ketamine Media

Novel new drugs derived from compounds like psilocybin, MDMA and more will soon join existing therapies like ketamine-assisted psychotherapy to combat the country’s crippling mental health problems. Psychedelic therapies like ketamine have shown the potential to be more effective than standard medication such as SSRIs, with psilocybin and MDMA showing similar or greater efficacy. With that in mind, creating a single comprehensive network was seen as an essential part of laying the groundwork for the future.

Currently, the PTN primarily serves as a hub for patients to find providers specializing in various forms of ketamine-assisted therapy and infusions. However, as medications continue to gain approval, like MDMA (currently entering phase three trials conducted by MAPS) and psilocybin (entering phase two trials with COMPASS Pathways), the network will expand to cover medical providers offering those services as well.

Expanding access to novel mental health treatments can provide significant benefits to the general public but is vitally important to the nation’s veteran population. Military veterans and first responders are 52% more likely to develop post-traumatic stress disorder (PTSD), a mental health condition associated with traumatic experiences. Veterans and first responders are also significantly more likely to experience depression and have much higher rates of suicide than the general population.

“As a veteran who’s dealt with PTSD and depression first hand, I can say that treatments like psilocybin, ketamine, and MDMA do work. Unlike many veterans, I’ve had the opportunity to experience the healing potential of psychedelics firsthand at retreats in legal countries. If veterans here at home (The United States) had access to this sort of therapy, we would likely see a significant reduction in veteran suicides and depression rates across the board.”
David Connell, Author, Cooking with Magic: The Psilocybin Cookbook and Senior Copywriter at Ketamine Media.

The potential benefits of psychedelic medicines go beyond veteran mental healthcare. End-of-life care, treatment-resistant depression, anxiety, and substance abuse disorders are just a few of the conditions that psychedelic compounds have shown promise for treating.

Tools like the Psychedelic Therapy Network will be an essential part of growing the reach of psychedelic medicine providers as therapies such as ketamine-assisted psychotherapy, MDMA-assisted therapy, and psilocybin treatments gain notoriety. Patients and providers will benefit from the suite of tools, connections, and educational resources offered by the PTN, furthering public awareness and knowledge regarding these potent tools for combating mental health conditions.

ABOUT KETAMINE MEDIA (KETA MEDIA, LLC)
Ketamine Media is a full-service multi-media marketing and advertising agency headquartered in Knoxville, Tennessee. Specializing in raising awareness about the clinical use of ketamine and other psychedelic medicine, Ketamine Media is the nation’s oldest and highest performing ketamine-focused advertising agency. Ketamine Media’s team offers a wealth of experience communicating with and connecting to individuals interested in exploring novel treatments for their mental healthcare. This specialized know-how is invaluable for their partners within the space, who need to reach patients in critical need of specialized care. If you are interested in partnering with Ketamine Media, the company can be contacted at:

Ketamine Media
611 King St NW
Suite 200B,
Knoxville, TN 37917

Phone: (800) 975-2291
Online: https://ketaminemedia.com

Here's What Happens When Psychedelics Meets AI

An emerging trend in some bioscience startups is the development of both cannabis and psychedelics products. One such company is Enveric Biosciences, headquartered in Naples, Florida, which hopes to leverage psychedelics-derived molecules for the mind and create synthetic cannabinoids for the body in the treatment of cancer. Enveric Biosciences focuses on synthesizing novel, tailored and […]

Continue reading

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed in early 2021 for AP-188 (“N,N-dimethyltryptamine” or “DMT”), the Company included novel salt forms of DMT. A novel salt form of a drug is a new and separate structure from the original comp

Continue reading